Skip to content
← Evidence library

CANCER EVIDENCE

FDA oncology source notices

FDA source notices. Approval notifications and safety communications preserved with their dates and original source text.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

This is a captured collection, not a complete or live list of approvals. A notification must be read for its exact indication, population and regimen; it is not a recommendation.

Safety communications

2026-02-05 · Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency
id
fda-b2a4254ca443dc00
event type
fda_safety_labeling_notification
event date
2026-02-05
title
Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency
drug or regimen
capecitabine and fluorouracil (5-FU)
approval date
Source null
approval type
Source null
approval type evidence
Not applicable: safety communication.
indication summary
FDA safety-labeling communication concerning DPD deficiency and capecitabine/fluorouracil; see exact notice text. No new oncology indication is asserted.
indication source text
The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers should be aware of the risks of DPD deficiency, inform patients prior to treatment about the potential for serious and life-threatening toxicities due to DPD deficiency, and test patients for genetic variants of DPYD prior to initiating treatment with capecitabine or 5-FU unless immediate treatment is necessary.
opening context blocks
  1. The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers should be aware of the risks of DPD deficiency, inform patients prior to treatment about the potential for serious and life-threatening toxicities due to DPD deficiency, and test patients for genetic variants of DPYD prior to initiating treatment with capecitabine or 5-FU unless immediate treatment is necessary.
  2. The DPYD gene encodes the enzyme DPD, which breaks down >80% of fluorouracil. Patients with certain homozygous or compound heterozygous variants in the DPYD gene, known to result in complete or near complete absence of DPD activity (complete DPD deficiency), are at increased risk for acute early-onset toxicity and serious, including fatal, adverse reactions (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity) when exposed to capecitabine or fluorouracil. Patients with partial DPD activity (partial DPD deficiency) may also have an increased risk of serious, including fatal, adverse reactions.
  3. The FDA recently approved revisions to the Xeloda (capecitabine) and 5-FU product labeling to provide further information on DPD deficiency. The following summarizes the key changes that were made to the labeling of both drugs:
  4. Boxed Warning: The Boxed Warning now highlights the risk of serious adverse reactions or death in patients with complete DPD deficiency. It also advises DPYD testing prior to initiating capecitabine or 5-FU, unless immediate treatment is necessary, and recommends avoiding use in patients with certain homozygous or compound heterozygous DYPD variants that result in complete DPD deficiency.
  5. Dosage and Administration: A new subsection, 2.1 Evaluation and Testing for DPD Deficiency Before Initiating capecitabine or 5-FU, has been added and instructs to avoid use of these drugs in patients known to have certain homozygous or compound heterozygous DYPD variants that result in complete DPD deficiency. For patients with partial DPD deficiency, dosing should be individualized.
  6. Warnings and Precautions: Reiterates that prior to initiating capecitabine or 5-FU, patients should be tested for genetic variants of the DPYD gene unless immediate treatment is necessary.
  7. Content current as of: 02/05/2026
tumor type mapping hints
mapping status
heuristic_requires_editorial_review
regulatory meaning
Safety communication, not a new drug/indication approval.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-02-05
index description
The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers should be aware of the risks of DPD deficiency, inform patients prior to treatment about the potential for serious and life-threatening toxicities due to DPD deficiency, and test patients for genetic variants of DPYD prior to initiating treatment with capecitabine or 5-FU unless immediate treatment is necessary.
provenance
retrieved at
2026-10-21T00:01:21.475569+00:00
local html
pages/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine.html
linked prescribing information
nct ids
quality flags
  1. safety_notice_not_approval_event
  2. tumor_mapping_unresolved
verification status
source_extracted_not_clinically_reviewed
2025-01-24 · Safety announcement: FDA highlights importance of DPD deficiency discussions with patients prior to capecitabine or 5FU treatment
id
fda-e4f57941f6e52243
event type
fda_safety_labeling_notification
event date
2025-01-24
title
Safety announcement: FDA highlights importance of DPD deficiency discussions with patients prior to capecitabine or 5FU treatment
drug or regimen
capecitabine and fluorouracil (5-FU)
approval date
Source null
approval type
Source null
approval type evidence
Not applicable: safety communication.
indication summary
FDA safety-labeling communication concerning DPD deficiency and capecitabine/fluorouracil; see exact notice text. No new oncology indication is asserted.
indication source text
The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers should be aware of the risks of DPD deficiency, inform patients prior to treatment about the potential for serious and life-threatening toxicities due to DPD deficiency, and discuss testing options for DPD deficiency with their patients.
opening context blocks
  1. The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers should be aware of the risks of DPD deficiency, inform patients prior to treatment about the potential for serious and life-threatening toxicities due to DPD deficiency, and discuss testing options for DPD deficiency with their patients.
  2. Fluoropyrimidines are a class of anti-cancer drugs that include fluorouracil (5-FU) and capecitabine, a prodrug of 5-FU. The DPYD gene encodes the enzyme DPD, which breaks down >80% of fluorouracil. Patients with certain homozygous or compound heterozygous variants in the DPYD gene, known to result in complete or near complete absence of DPD activity (complete DPD deficiency), are at increased risk for acute early-onset toxicity and serious, including fatal, adverse reactions (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity (partial DPD deficiency) may also have increased risk of serious, including fatal, adverse reactions.
tumor type mapping hints
mapping status
heuristic_requires_editorial_review
regulatory meaning
Safety communication, not a new drug/indication approval.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/safety-announcement-fda-highlights-importance-dpd-deficiency-discussions-patients-prior-capecitabine
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/safety-announcement-fda-highlights-importance-dpd-deficiency-discussions-patients-prior-capecitabine
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-01-24
index description
The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers should be aware of the risks of DPD deficiency, inform patients prior to treatment about the potential for serious and life-threatening toxicities due to DPD deficiency, and discuss testing options for DPD deficiency with their patients.
provenance
retrieved at
2026-10-21T00:02:13.788387+00:00
local html
pages/safety-announcement-fda-highlights-importance-dpd-deficiency-discussions-patients-prior-capecitabine.html
linked prescribing information
nct ids
quality flags
  1. safety_notice_not_approval_event
  2. tumor_mapping_unresolved
verification status
source_extracted_not_clinically_reviewed

Oncology approval notifications

2026-10-19 · FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer
id
fda-01ffc493b51b46ed
event type
fda_oncology_approval_notification
event date
2026-10-19
title
FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer
drug or regimen
dostarlimab
approval date
2026-10-19
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved dostarlimab for adults with Stage II/III locally advanced rectal cancer that is microsatellite instability high or mismatch repair deficient, as determined by an FDA-authorized test for solid tumors.
indication source text
On October 19, 2026, the Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized test for solid tumors.
opening context blocks
  1. On October 19, 2026, the Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized test for solid tumors.
tumor type mapping hints
  1. colorectal
  2. solid-tumors
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-10-19
index description
On October 19, 2026, the Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized test for solid tumors.
provenance
retrieved at
2026-10-21T00:00:39.750175+00:00
local html
pages/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer.html
linked prescribing information
nct ids
  1. NCT04165772
  2. NCT05723562
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-10-14 · FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
id
fda-fc114ac31528e5cd
event type
fda_oncology_approval_notification
event date
2026-10-14
title
FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
drug or regimen
an expanded indication
approval date
2026-10-14
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved nogapendekin alfa inbakicept-pmln with Bacillus Calmette-Guérin for adults with BCG-unresponsive non-muscle invasive bladder cancer . This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors to include patients with high-grade papillary-only tumors.
indication source text
On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors to include patients with high-grade papillary-only tumors.
opening context blocks
  1. On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors to include patients with high-grade papillary-only tumors.
tumor type mapping hints
  1. bladder
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-10-14
index description
On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors to include patients with high-grade papillary-only tumors.
provenance
retrieved at
2026-10-21T00:00:41.630191+00:00
local html
pages/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle.html
linked prescribing information
nct ids
  1. NCT03022825
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-10-08 · FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer
id
fda-cfbb3ec7ec7dc677
event type
fda_oncology_approval_notification
event date
2026-10-08
title
FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer
drug or regimen
atezolizumab in combination with chemotherapy
approval date
2026-10-08
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved atezolizumab in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
indication source text
On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
opening context blocks
  1. On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
tumor type mapping hints
  1. colorectal
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-10-08
index description
On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
provenance
retrieved at
2026-10-21T00:00:40.801795+00:00
local html
pages/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer.html
linked prescribing information
nct ids
  1. NCT02912559
quality flags
  1. multiple_regulatory_actions_require_indication_split
verification status
source_extracted_not_clinically_reviewed
2026-10-07 · FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer
id
fda-9aa25464ecc1dab6
event type
fda_oncology_approval_notification
event date
2026-10-07
title
FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer
drug or regimen
tucatinib with trastuzumab and pertuzumab
approval date
2026-10-07
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved tucatinib in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
indication source text
On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
opening context blocks
  1. On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-10-07
index description
On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
provenance
retrieved at
2026-10-21T00:00:42.682584+00:00
local html
pages/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer.html
linked prescribing information
nct ids
  1. NCT05132582
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-10-02 · FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
id
fda-68decff2f02aa414
event type
fda_oncology_approval_notification
event date
2026-10-02
title
FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
drug or regimen
pirtobrutinib
approval date
2026-10-02
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved pirtobrutinib for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.
indication source text
On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.
opening context blocks
  1. On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.
tumor type mapping hints
  1. lymphoma
  2. leukemia
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-10-02
index description
On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.
provenance
retrieved at
2026-10-21T00:00:43.630988+00:00
local html
pages/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic.html
linked prescribing information
nct ids
  1. NCT05023980
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-09-24 · FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component
id
fda-347289d277bb85ef
event type
fda_oncology_approval_notification
event date
2026-09-24
title
FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component
drug or regimen
belzutifan in combination with lenvatinib
approval date
2026-09-24
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved belzutifan in combination with lenvatinib for adults with advanced renal cell carcinoma with a clear cell component following a programmed death receptor-1 or programmed death-ligand 1 inhibitor.
indication source text
On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
opening context blocks
  1. On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
tumor type mapping hints
  1. kidney
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell-component
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell-component
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-09-24
index description
On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
provenance
retrieved at
2026-10-21T00:00:44.732466+00:00
local html
pages/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell-component.html
linked prescribing information
nct ids
  1. NCT04586231
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-09-23 · FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma
id
fda-52d9a9858b2d4418
event type
fda_oncology_approval_notification
event date
2026-09-23
title
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma
drug or regimen
lirafugratinib
approval date
2026-09-23
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved lirafugratinib, a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement.
indication source text
On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.
opening context blocks
  1. On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.
tumor type mapping hints
  1. biliary
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-09-23
index description
On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.
provenance
retrieved at
2026-10-21T00:00:46.248501+00:00
local html
pages/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic.html
linked prescribing information
nct ids
  1. NCT04526106
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-09-18 · FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
id
fda-d6813188be521b89
event type
fda_oncology_approval_notification
event date
2026-09-18
title
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
drug or regimen
imlunestrant in combination with abemaciclib
approval date
2026-09-18
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved imlunestrant in combination with abemaciclib, for adults with estrogen receptor -positive, human epidermal growth factor receptor 2 -negative, estrogen receptor 1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.
indication source text
On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.
opening context blocks
  1. On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.
  2. FDA also approved the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with imlunestrant and abemaciclib.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-09-18
index description
On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.
provenance
retrieved at
2026-10-21T00:00:48.248917+00:00
local html
pages/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or.html
linked prescribing information
nct ids
  1. NCT04975308
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-09-09 · FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer
id
fda-31fccf3ff6d99d7d
event type
fda_oncology_approval_notification
event date
2026-09-09
title
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer
drug or regimen
sevabertinib
approval date
2026-09-09
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved sevabertinib, a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.
indication source text
On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
opening context blocks
  1. On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
  2. This approval expands the existing indication for sevabertinib, which was previously granted accelerated approval for adult patients with locally advanced or metastatic non-squamous NSCLC with HER2 (ERBB2) TKD activating mutations who had received prior systemic therapy.
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-09-09
index description
On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
provenance
retrieved at
2026-10-21T00:00:50.366238+00:00
local html
pages/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small.html
linked prescribing information
nct ids
  1. NCT05099172
quality flags
  1. same_day_event_verify_label_availability
verification status
source_extracted_not_clinically_reviewed
2026-09-04 · FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer
id
fda-29ff88a8fe51d0cc
event type
fda_oncology_approval_notification
event date
2026-09-04
title
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer
drug or regimen
camizestrant with a CDK4/6 inhibitor
approval date
2026-09-04
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved camizestrant, an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor for adults with hormone receptor -positive, human epidermal growth factor receptor 2 -negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
indication source text
On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
opening context blocks
  1. On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
  2. FDA also approved the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with camizestrant.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-09-04
index description
On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
provenance
retrieved at
2026-10-21T00:00:50.836121+00:00
local html
pages/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative.html
linked prescribing information
nct ids
  1. NCT04964934
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-08-26 · FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
id
fda-fc4a8b5bcf8bfd67
event type
fda_oncology_approval_notification
event date
2026-08-26
title
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
drug or regimen
daraxonrasib
approval date
2026-08-26
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved daraxonrasib, an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
indication source text
On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
opening context blocks
  1. On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
tumor type mapping hints
  1. pancreatic
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-08-26
index description
On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
provenance
retrieved at
2026-10-21T00:00:50.964620+00:00
local html
pages/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma.html
linked prescribing information
nct ids
  1. NCT06625320
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-08-25 · FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma
id
fda-6ffd9790ac8016fd
event type
fda_oncology_approval_notification
event date
2026-08-25
title
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma
drug or regimen
zanidatamab-hrii and tislelizumab-jsgr
approval date
2026-08-25
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved zanidatamab-hrii :
indication source text
On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals):
opening context blocks
  1. On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals):
  2. in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and
  3. in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.
  4. Today, the FDA also approved two companion diagnostic devices, the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and the VENTANA HER2 Dual ISH DNA Probe Cocktail (Ventana Medical Systems, Inc./Roche Diagnostics), for identifying patients with HER2-positive (IHC3+ or IHC2+/ISH+) gastric, gastroesophageal junction, and esophageal adenocarcinoma for treatment with Ziihera, consistent with the approved drug labeling.
tumor type mapping hints
  1. gastric
  2. esophageal
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanidatamab-hrii-and-tislelizumab-jsgr-her2-positive-gastric-gastroesophageal-junction
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanidatamab-hrii-and-tislelizumab-jsgr-her2-positive-gastric-gastroesophageal-junction
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-08-25
index description
On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir
provenance
retrieved at
2026-10-21T00:00:52.116651+00:00
local html
pages/fda-approves-zanidatamab-hrii-and-tislelizumab-jsgr-her2-positive-gastric-gastroesophageal-junction.html
linked prescribing information
nct ids
  1. NCT05152147
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-08-13 · FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
id
fda-9b5c25c72ccbc4de
event type
fda_oncology_approval_notification
event date
2026-08-13
title
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
drug or regimen
iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone
approval date
2026-08-13
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved iberdomide in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
indication source text
On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
opening context blocks
  1. On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
tumor type mapping hints
  1. myeloma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-08-13
index description
On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
provenance
retrieved at
2026-10-21T00:00:54.448762+00:00
local html
pages/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone.html
linked prescribing information
nct ids
  1. NCT04975997
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-08-06 · FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma
id
fda-f02afa7b64e90adf
event type
fda_oncology_approval_notification
event date
2026-08-06
title
FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma
drug or regimen
vusolimogene oderparepvec-wtpg in combination with nivolumab
approval date
2026-08-06
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved vusolimogene oderparepvec-wtpg, a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 -blocking antibody-based regimen.
indication source text
On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
opening context blocks
  1. On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
tumor type mapping hints
  1. melanoma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-08-06
index description
On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
provenance
retrieved at
2026-10-21T00:00:55.581816+00:00
local html
pages/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma.html
linked prescribing information
nct ids
  1. NCT03767348
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-07-31 · FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer
id
fda-036eff4becf1a0e2
event type
fda_oncology_approval_notification
event date
2026-07-31
title
FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer
drug or regimen
lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy
approval date
2026-07-31
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved lutetium Lu 177 vipivotide tetraxetan in combination with androgen receptor pathway inhibitor therapy for adults with prostate-specific membrane antigen -positive metastatic androgen pathway modulation-naïve or-sensitive prostate cancer .
indication source text
On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
opening context blocks
  1. On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
  2. Patients with mAPMN/S prostate cancer should be selected for Pluvicto using Locametz (active ingredient gallium Ga 68 gozetotide) or another approved PSMA positron emission tomography (PET) product based on PSMA expression in tumors.
tumor type mapping hints
  1. prostate
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-07-31
index description
On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
provenance
retrieved at
2026-10-21T00:00:55.600154+00:00
local html
pages/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy.html
linked prescribing information
nct ids
  1. NCT04720157
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-07-22 · FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
id
fda-e0f74c6ff06b5fd4
event type
fda_oncology_approval_notification
event date
2026-07-22
title
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
drug or regimen
zidesamtinib
approval date
2026-07-22
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved zidesamtinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received at least one prior ROS1 tyrosine kinase inhibitor .
indication source text
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
opening context blocks
  1. On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-07-22
index description
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
provenance
retrieved at
2026-10-21T00:00:55.509683+00:00
local html
pages/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer.html
linked prescribing information
nct ids
  1. NCT05118789
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-07-14 · FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
id
fda-d52a86815b17155d
event type
fda_oncology_approval_notification
event date
2026-07-14
title
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
drug or regimen
selpercatinib
approval date
2026-07-14
approval type
traditional
approval type evidence
traditional explicitly stated in title/opening
indication summary
FDA approved selpercatinib for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. Selpercatinib received accelerated approval for this indication for adult patients in 2022 and for pediatric patients two years of age and older in 2024.
indication source text
On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. Selpercatinib received accelerated approval for this indication for adult patients in 2022 and for pediatric patients two years of age and older in 2024.
opening context blocks
  1. On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. Selpercatinib received accelerated approval for this indication for adult patients in 2022 and for pediatric patients two years of age and older in 2024.
tumor type mapping hints
  1. solid-tumors
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-07-14
index description
On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
provenance
retrieved at
2026-10-21T00:00:57.349942+00:00
local html
pages/fda-grants-traditional-approval-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive.html
linked prescribing information
nct ids
  1. NCT03157128
  2. NCT03899792
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-07-14 · FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
id
fda-cfcc707359fdc22f
event type
fda_oncology_approval_notification
event date
2026-07-14
title
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
drug or regimen
gedatolisib with fulvestrant, with or without palbociclib
approval date
2026-07-14
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor -positive, human epidermal growth factor receptor 2 -negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
indication source text
On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
opening context blocks
  1. On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-07-14
index description
On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
provenance
retrieved at
2026-10-21T00:00:56.482535+00:00
local html
pages/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally.html
linked prescribing information
nct ids
  1. NCT05501886
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-07-10 · FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
id
fda-0403089146861ff3
event type
fda_oncology_approval_notification
event date
2026-07-10
title
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
drug or regimen
pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv
approval date
2026-07-10
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each in combination with enfortumab vedotin-ejfv as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer . This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
indication source text
On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
opening context blocks
  1. On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
tumor type mapping hints
  1. bladder
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-07-10
index description
On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
provenance
retrieved at
2026-10-21T00:00:58.393546+00:00
local html
pages/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin.html
linked prescribing information
nct ids
  1. NCT04700124
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-07-09 · FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications
id
fda-99375b4186db616c
event type
fda_oncology_approval_notification
event date
2026-07-09
title
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications
drug or regimen
isatuximab-irfc
approval date
2026-07-09
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved isatuximab-irfc for subcutaneous injection for multiple myeloma indications. The specific indications approved for Isatuximab-irfc are:
indication source text
On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications. The specific indications approved for Isatuximab-irfc are:
opening context blocks
  1. On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications. The specific indications approved for Isatuximab-irfc are:
  2. in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor,
  3. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, and
  4. in combination with bortezomib, lenalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for an autologous stem cell transplant.
tumor type mapping hints
  1. myeloma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-subcutaneous-injection-multiple-myeloma-indications
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-subcutaneous-injection-multiple-myeloma-indications
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-07-09
index description
On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.
provenance
retrieved at
2026-10-21T00:00:59.372265+00:00
local html
pages/fda-approves-isatuximab-irfc-subcutaneous-injection-multiple-myeloma-indications.html
linked prescribing information
nct ids
  1. NCT05405166
  2. NCT05704049
  3. NCT05889221
quality flags
  1. possible_multiple_indications_review
verification status
source_extracted_not_clinically_reviewed
2026-06-30 · FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
id
fda-960b36951050035f
event type
fda_oncology_approval_notification
event date
2026-06-30
title
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
drug or regimen
allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq
approval date
2026-06-30
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell and T cells-vldq for use in matched donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease -free survival, in the treatment of adults with hematological malignancies.
indication source text
On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
opening context blocks
  1. On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
tumor type mapping hints
  1. hematologic-malignancies
  2. graft-versus-host-disease
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-allogeneic-regulatory-t-cell-based-immunotherapy-hspc-and-t-cells-vldq-use-matched
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-allogeneic-regulatory-t-cell-based-immunotherapy-hspc-and-t-cells-vldq-use-matched
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-06-30
index description
On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
provenance
retrieved at
2026-10-21T00:01:00.349298+00:00
local html
pages/fda-approves-allogeneic-regulatory-t-cell-based-immunotherapy-hspc-and-t-cells-vldq-use-matched.html
linked prescribing information
nct ids
  1. NCT05316701
quality flags
  1. may_be_supportive_care_or_nonmalignant_condition
verification status
source_extracted_not_clinically_reviewed
2026-06-24 · FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
id
fda-679b968656ef28cf
event type
fda_oncology_approval_notification
event date
2026-06-24
title
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
drug or regimen
palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy
approval date
2026-06-24
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
indication source text
On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
opening context blocks
  1. On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-palbociclib-trastuzumab-or-without-pertuzumab-and-endocrine-therapy-maintenance
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-palbociclib-trastuzumab-or-without-pertuzumab-and-endocrine-therapy-maintenance
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-06-24
index description
On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
provenance
retrieved at
2026-10-21T00:01:02.320465+00:00
local html
pages/fda-approves-palbociclib-trastuzumab-or-without-pertuzumab-and-endocrine-therapy-maintenance.html
linked prescribing information
nct ids
  1. NCT02947685
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-06-24 · FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
id
fda-49e2a73345425f2f
event type
fda_oncology_approval_notification
event date
2026-06-24
title
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
drug or regimen
sacituzumab govitecan-hziy
approval date
2026-06-24
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved sacituzumab govitecan-hziy for two indications in adults with triple-negative breast cancer . The first indication, supported by ASCENT-03, is for sacituzumab govitecan-hziy as a single agent for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. The second indication, supported by ASCENT-04/KEYNOTE D-19, is for sacituzumab govitecan-hziy in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 as determined by an FDA-authorized test.
indication source text
On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC). The first indication, supported by ASCENT-03, is for sacituzumab govitecan-hziy as a single agent for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. The second indication, supported by ASCENT-04/KEYNOTE D-19, is for sacituzumab govitecan-hziy in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test.
opening context blocks
  1. On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC). The first indication, supported by ASCENT-03, is for sacituzumab govitecan-hziy as a single agent for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. The second indication, supported by ASCENT-04/KEYNOTE D-19, is for sacituzumab govitecan-hziy in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-06-24
index description
On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
provenance
retrieved at
2026-10-21T00:01:01.631251+00:00
local html
pages/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line.html
linked prescribing information
nct ids
  1. NCT05382286
  2. NCT05382299
quality flags
  1. possible_multiple_indications_review
verification status
source_extracted_not_clinically_reviewed
2026-06-12 · FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
id
fda-b7661f27f59bbecb
event type
fda_oncology_approval_notification
event date
2026-06-12
title
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
drug or regimen
capivasertib with abiraterone and prednisone
approval date
2026-06-12
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved capivasertib in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is PTEN-deficient as detected by an FDA-authorized test.
indication source text
On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
opening context blocks
  1. On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
  2. The FDA also approved the VENTANA PTEN (SP218) RxDx Assay (Ventana Medical Systems, Inc./Roche Diagnostics) as a companion diagnostic device to identify patients with PTEN-deficient prostate cancer for treatment with capivasertib.
tumor type mapping hints
  1. prostate
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-abiraterone-and-prednisone-pten-deficient-androgen-pathway-modulation
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-abiraterone-and-prednisone-pten-deficient-androgen-pathway-modulation
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-06-12
index description
On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
provenance
retrieved at
2026-10-21T00:01:03.348892+00:00
local html
pages/fda-approves-capivasertib-abiraterone-and-prednisone-pten-deficient-androgen-pathway-modulation.html
linked prescribing information
nct ids
  1. NCT04305496
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-06-12 · FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
id
fda-69399853a62eefe0
event type
fda_oncology_approval_notification
event date
2026-06-12
title
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
drug or regimen
belzutifan with pembrolizumab
approval date
2026-06-12
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved belzutifan in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
indication source text
On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
opening context blocks
  1. On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
tumor type mapping hints
  1. kidney
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-06-12
index description
On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
provenance
retrieved at
2026-10-21T00:01:04.395242+00:00
local html
pages/fda-approves-belzutifan-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma.html
linked prescribing information
nct ids
  1. NCT05239728
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-05-28 · FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer
id
fda-c07ece06c8530681
event type
fda_oncology_approval_notification
event date
2026-05-28
title
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer
drug or regimen
durvalumab in combination with Bacillus Calmette-Guerin
approval date
2026-05-28
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved durvalumab in combination with Bacillus Calmette-Guerin for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer .
indication source text
On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
opening context blocks
  1. On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
tumor type mapping hints
  1. bladder
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-05-28
index description
On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
provenance
retrieved at
2026-10-21T00:01:06.591292+00:00
local html
pages/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder.html
linked prescribing information
nct ids
  1. NCT03528694
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-05-27 · FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy
id
fda-d96394837965add4
event type
fda_oncology_approval_notification
event date
2026-05-27
title
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy
drug or regimen
pivekimab sunirine-pvzy
approval date
2026-05-27
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved pivekimab sunirine-pvzy, a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm .
indication source text
On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
opening context blocks
  1. On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
tumor type mapping hints
  1. bpdcn
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-05-27
index description
On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
provenance
retrieved at
2026-10-21T00:01:06.752070+00:00
local html
pages/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare.html
linked prescribing information
nct ids
  1. NCT03386513
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-05-22 · FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer
id
fda-06e75bbbea9cc2b5
event type
fda_oncology_approval_notification
event date
2026-05-22
title
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer
drug or regimen
datopotamab deruxtecan-dlnk
approval date
2026-05-22
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved datopotamab deruxtecan-dlnk for adult patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.
indication source text
On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
opening context blocks
  1. On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-05-22
index description
On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
provenance
retrieved at
2026-10-21T00:01:07.663507+00:00
local html
pages/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer.html
linked prescribing information
nct ids
  1. NCT05374512
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-05-15 · FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer
id
fda-a25466af65cfcdc1
event type
fda_oncology_approval_notification
event date
2026-05-15
title
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer
drug or regimen
fam-trastuzumab deruxtecan-nxki
approval date
2026-05-15
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved fam-trastuzumab deruxtecan-nxki for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab, for the neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab and taxane-based treatment.
indication source text
On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
opening context blocks
  1. On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
  2. FDA also approved two companion diagnostic devices, the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and the VENTANA HER2 Dual ISH DNA Probe Cocktail, both for identifying HER2-positive (IHC3+ or ISH+) patients for treatment with T-DXd, consistent with the approved drug labeling.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-two-separate-indications-fam-trastuzumab-deruxtecan-nxki-her2-positive-early-stage
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-two-separate-indications-fam-trastuzumab-deruxtecan-nxki-her2-positive-early-stage
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-05-15
index description
On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
provenance
retrieved at
2026-10-21T00:01:08.436167+00:00
local html
pages/fda-approves-two-separate-indications-fam-trastuzumab-deruxtecan-nxki-her2-positive-early-stage.html
linked prescribing information
nct ids
  1. NCT04622319
  2. NCT05113251
quality flags
  1. possible_multiple_indications_review
verification status
source_extracted_not_clinically_reviewed
2026-05-15 · FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease
id
fda-7f6ca1fc3c4ca109
event type
fda_oncology_approval_notification
event date
2026-05-15
title
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease
drug or regimen
atezolizumab
approval date
2026-05-15
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved atezolizumab and atezolizumab and hyaluronidase-tqjs as adjuvant treatments for adults with muscle invasive bladder cancer after cystectomy who have circulating tumor DNA molecular residual disease as determined by an FDA-authorized test.
indication source text
On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
opening context blocks
  1. On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
  2. Today, the FDA also approved Signatera CDx (Natera, Inc.) as a companion diagnostic device to select patients with MIBC after cystectomy who have ctDNA MRD for adjuvant treatment with Tecentriq or with Tecentriq Hybreza.
tumor type mapping hints
  1. bladder
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-muscle-invasive-bladder-cancer-patients-molecular
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-muscle-invasive-bladder-cancer-patients-molecular
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-05-15
index description
On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
provenance
retrieved at
2026-10-21T00:01:09.416106+00:00
local html
pages/fda-approves-atezolizumab-adjuvant-treatment-muscle-invasive-bladder-cancer-patients-molecular.html
linked prescribing information
nct ids
  1. NCT04660344
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-05-13 · FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma
id
fda-e3ca63e98a156ea8
event type
fda_oncology_approval_notification
event date
2026-05-13
title
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma
drug or regimen
sonrotoclax
approval date
2026-05-13
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved sonrotoclax, a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor.
indication source text
On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
opening context blocks
  1. On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
tumor type mapping hints
  1. lymphoma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sonrotoclax-relapsed-or-refractory-mantle-cell-lymphoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sonrotoclax-relapsed-or-refractory-mantle-cell-lymphoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-05-13
index description
On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
provenance
retrieved at
2026-10-21T00:01:11.425904+00:00
local html
pages/fda-grants-accelerated-approval-sonrotoclax-relapsed-or-refractory-mantle-cell-lymphoma.html
linked prescribing information
nct ids
  1. NCT05471843
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-05-13 · FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia
id
fda-990c1df07ad6d6a2
event type
fda_oncology_approval_notification
event date
2026-05-13
title
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia
drug or regimen
oral combination of decitabine and cedazuridine tablets with venetoclax
approval date
2026-05-13
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved an oral combination of decitabine and cedazuridine tablets with venetoclax for the treatment of newly diagnosed acute myeloid leukemia in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
indication source text
On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
opening context blocks
  1. On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
tumor type mapping hints
  1. leukemia
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-05-13
index description
On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
provenance
retrieved at
2026-10-21T00:01:10.481828+00:00
local html
pages/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute.html
linked prescribing information
nct ids
  1. NCT04657081
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-05-08 · FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma
id
fda-da34fd1212e64f9b
event type
fda_oncology_approval_notification
event date
2026-05-08
title
FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma
drug or regimen
zenocutuzumab-zbco
approval date
2026-05-08
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved zenocutuzumab-zbco for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
indication source text
On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
opening context blocks
  1. On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
  2. This application is part of the FDA Commissioner’s National Priority Review Voucher (CNPV) pilot program, which is designed to accelerate the review of products with the potential to address key national priorities.
tumor type mapping hints
  1. biliary
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zenocutuzumab-zbco-advanced-unresectable-or-metastatic-cholangiocarcinoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zenocutuzumab-zbco-advanced-unresectable-or-metastatic-cholangiocarcinoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-05-08
index description
On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
provenance
retrieved at
2026-10-21T00:01:12.501857+00:00
local html
pages/fda-approves-zenocutuzumab-zbco-advanced-unresectable-or-metastatic-cholangiocarcinoma.html
linked prescribing information
nct ids
  1. NCT02912949
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-05-01 · FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
id
fda-139bc569cd69b40c
event type
fda_oncology_approval_notification
event date
2026-05-01
title
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
drug or regimen
vepdegestrant
approval date
2026-05-01
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved vepdegestrant, a heterobifunctional protein degrader, for adults with estrogen receptor -positive, human epidermal growth factor receptor 2 -negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
indication source text
On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
opening context blocks
  1. On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
  2. FDA also approved the Guardant360 CDx as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with vepdegestrant.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-05-01
index description
On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
provenance
retrieved at
2026-10-21T00:01:13.462570+00:00
local html
pages/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast.html
linked prescribing information
nct ids
  1. NCT05654623
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-03-25 · FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
id
fda-d4ea94bc27b96b36
event type
fda_oncology_approval_notification
event date
2026-03-25
title
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
drug or regimen
relacorilant with nab-paclitaxel
approval date
2026-03-25
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved relacorilant, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
indication source text
On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
opening context blocks
  1. On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
tumor type mapping hints
  1. ovarian
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relacorilant-nab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relacorilant-nab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-03-25
index description
On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
provenance
retrieved at
2026-10-21T00:01:14.454850+00:00
local html
pages/fda-approves-relacorilant-nab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or.html
linked prescribing information
nct ids
  1. NCT05257408
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-03-20 · FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma
id
fda-491ef4b41b9bb54f
event type
fda_oncology_approval_notification
event date
2026-03-20
title
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma
drug or regimen
nivolumab with chemotherapy
approval date
2026-03-20
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved nivolumab with doxorubicin, vinblastine, and dacarbazine for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma . The FDA also granted traditional approval to nivolumab for the following indications in adults with relapsed or refractory cHL:
indication source text
On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL). The FDA also granted traditional approval to nivolumab for the following indications in adults with relapsed or refractory cHL:
opening context blocks
  1. On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL). The FDA also granted traditional approval to nivolumab for the following indications in adults with relapsed or refractory cHL:
  2. after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin
  3. after three or more lines of systemic therapy that includes autologous HSCT.
  4. Nivolumab received accelerated approval for these indications in 2016 and 2017, respectively.
tumor type mapping hints
  1. lymphoma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-chemotherapy-previously-untreated-hodgkin-lymphoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-chemotherapy-previously-untreated-hodgkin-lymphoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-03-20
index description
On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
provenance
retrieved at
2026-10-21T00:01:15.467006+00:00
local html
pages/fda-approves-nivolumab-chemotherapy-previously-untreated-hodgkin-lymphoma.html
linked prescribing information
nct ids
  1. NCT03907488
quality flags
  1. possible_multiple_indications_review
  2. multiple_regulatory_actions_require_indication_split
verification status
source_extracted_not_clinically_reviewed
2026-03-05 · FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma
id
fda-b050e96dd06339f0
event type
fda_oncology_approval_notification
event date
2026-03-05
title
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma
drug or regimen
teclistamab in combination with daratumumab hyaluronidase-fihj
approval date
2026-03-05
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved teclistamab in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
indication source text
On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
opening context blocks
  1. On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
  2. Today’s approval also converts the accelerated approval to traditional approval for teclistamab, as monotherapy, in adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Teclistamab received accelerated approval for this indication in 2022.
  3. This application is part of the FDA Commissioner’s National Priority Review Voucher (CNPV) pilot program, which is designed to accelerate the review of products with the potential to address key national priorities.
tumor type mapping hints
  1. myeloma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-combination-daratumumab-hyaluronidase-fihj-relapsed-or-refractory-multiple
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-combination-daratumumab-hyaluronidase-fihj-relapsed-or-refractory-multiple
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-03-05
index description
On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
provenance
retrieved at
2026-10-21T00:01:16.470446+00:00
local html
pages/fda-approves-teclistamab-combination-daratumumab-hyaluronidase-fihj-relapsed-or-refractory-multiple.html
linked prescribing information
nct ids
  1. NCT05083169
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-02-26 · FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer
id
fda-3a7f03155778019c
event type
fda_oncology_approval_notification
event date
2026-02-26
title
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer
drug or regimen
zongertinib
approval date
2026-02-26
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved zongertinib, a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.
indication source text
On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
opening context blocks
  1. On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
  2. This application is part of the FDA Commissioner’s National Priority Review Voucher (CNPV) pilot program, which is designed to accelerate the review of products with the potential to address key national priorities.
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-unresectable-or-metastatic-non-squamous-non-small-cell
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-unresectable-or-metastatic-non-squamous-non-small-cell
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-02-26
index description
On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
provenance
retrieved at
2026-10-21T00:01:17.480546+00:00
local html
pages/fda-grants-accelerated-approval-zongertinib-unresectable-or-metastatic-non-squamous-non-small-cell.html
linked prescribing information
nct ids
  1. NCT04886804
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-02-24 · FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation
id
fda-d5666ec96b2af4ed
event type
fda_oncology_approval_notification
event date
2026-02-24
title
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation
drug or regimen
encorafenib
approval date
2026-02-24
approval type
traditional
approval type evidence
traditional explicitly stated in title/opening
indication summary
FDA approved encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
indication source text
On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
opening context blocks
  1. On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
tumor type mapping hints
  1. colorectal
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-02-24
index description
On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
provenance
retrieved at
2026-10-21T00:01:18.483192+00:00
local html
pages/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation.html
linked prescribing information
nct ids
  1. NCT04607421
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-02-19 · FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma
id
fda-2484637c7ad88112
event type
fda_oncology_approval_notification
event date
2026-02-19
title
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma
drug or regimen
acalabrutinib with venetoclax
approval date
2026-02-19
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved acalabrutinib tablets and capsules in combination with venetoclax for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma .
indication source text
On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
opening context blocks
  1. On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
tumor type mapping hints
  1. lymphoma
  2. leukemia
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-acalabrutinib-venetoclax-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-acalabrutinib-venetoclax-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-02-19
index description
On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
provenance
retrieved at
2026-10-21T00:01:19.477783+00:00
local html
pages/fda-approves-acalabrutinib-venetoclax-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma.html
linked prescribing information
nct ids
  1. NCT03836261
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-02-10 · FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
id
fda-de7303eac1be47e8
event type
fda_oncology_approval_notification
event date
2026-02-10
title
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
drug or regimen
pembrolizumab with paclitaxel
approval date
2026-02-10
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved pembrolizumab as well as pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
indication source text
On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
opening context blocks
  1. On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
  2. FDA also approved the PD-L1 IHC 22C3 pharmDx (Agilent Technologies, Inc) as a companion diagnostic device to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) for treatment with pembrolizumab.
tumor type mapping hints
  1. ovarian
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-02-10
index description
On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
provenance
retrieved at
2026-10-21T00:01:20.513344+00:00
local html
pages/fda-approves-pembrolizumab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or.html
linked prescribing information
nct ids
  1. NCT05116189
quality flags
verification status
source_extracted_not_clinically_reviewed
2026-01-27 · FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
id
fda-af9011a2d75e5c91
event type
fda_oncology_approval_notification
event date
2026-01-27
title
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
drug or regimen
daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone
approval date
2026-01-27
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant .
indication source text
On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
opening context blocks
  1. On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
tumor type mapping hints
  1. myeloma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2026-01-27
index description
On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
provenance
retrieved at
2026-10-21T00:01:22.510324+00:00
local html
pages/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly.html
linked prescribing information
nct ids
  1. NCT03652064
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-12-17 · FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection
id
fda-85818647aa43a4e8
event type
fda_oncology_approval_notification
event date
2025-12-17
title
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection
drug or regimen
amivantamab and hyaluronidase-lpuj
approval date
2025-12-17
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved amivantamab and hyaluronidase-lpuj for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab . See the prescribing information for the specific indications.
indication source text
On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
opening context blocks
  1. On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
tumor type mapping hints
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-and-hyaluronidase-lpuj-subcutaneous-injection
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-and-hyaluronidase-lpuj-subcutaneous-injection
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-12-17
index description
On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
provenance
retrieved at
2026-10-21T00:01:23.494675+00:00
local html
pages/fda-approves-amivantamab-and-hyaluronidase-lpuj-subcutaneous-injection.html
linked prescribing information
nct ids
quality flags
  1. tumor_mapping_unresolved
  2. possible_multiple_indications_review
verification status
source_extracted_not_clinically_reviewed
2025-12-17 · FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer
id
fda-2f7bc8b820239b15
event type
fda_oncology_approval_notification
event date
2025-12-17
title
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer
drug or regimen
rucaparib
approval date
2025-12-17
approval type
regular
approval type evidence
regular explicitly stated in title/opening
indication summary
FDA approved rucaparib for adults with a deleterious BRCA mutation -associated metastatic castration-resistant prostate cancer previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic . Rucaparib was granted accelerated approval in 2020 for a similar indication.
indication source text
On December 17, 2025, the Food and Drug Administration (FDA) approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx). Rucaparib was granted accelerated approval in 2020 for a similar indication.
opening context blocks
  1. On December 17, 2025, the Food and Drug Administration (FDA) approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx). Rucaparib was granted accelerated approval in 2020 for a similar indication.
tumor type mapping hints
  1. prostate
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-12-17
index description
On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).
provenance
retrieved at
2026-10-21T00:01:24.539766+00:00
local html
pages/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer.html
linked prescribing information
nct ids
  1. NCT02975934
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-12-15 · FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer
id
fda-838a85e7ab9c5846
event type
fda_oncology_approval_notification
event date
2025-12-15
title
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer
drug or regimen
fam-trastuzumab deruxtecan-nxki with pertuzumab
approval date
2025-12-15
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved fam-trastuzumab deruxtecan-nxki in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer as determined by an FDA-approved test.
indication source text
On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
opening context blocks
  1. On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
  2. FDA also approved the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and HER2 Dual ISH DNA Probe Cocktail as companion diagnostic devices for selecting HER2-positive (HER2 IHC3+ or ISH+) breast cancer patients for treatment with fam-trastuzumab deruxtecan-nxki in combination with pertuzumab.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive
evidence source url
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-12-15
index description
On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
provenance
retrieved at
2026-10-21T00:01:25.506680+00:00
local html
pages/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive.html
linked prescribing information
nct ids
  1. NCT04784715
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-12-12 · FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer
id
fda-3afb067b5b05cacc
event type
fda_oncology_approval_notification
event date
2025-12-12
title
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer
drug or regimen
niraparib and abiraterone acetate plus prednisone
approval date
2025-12-12
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved niraparib and abiraterone acetate with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer, as determined by an FDA-approved test.
indication source text
On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
opening context blocks
  1. On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
tumor type mapping hints
  1. prostate
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca2-mutated-metastatic-castration
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca2-mutated-metastatic-castration
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-12-12
index description
On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
provenance
retrieved at
2026-10-21T00:01:26.546634+00:00
local html
pages/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca2-mutated-metastatic-castration.html
linked prescribing information
nct ids
  1. NCT04497844
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-12-04 · FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma
id
fda-9123ee1df52ccb91
event type
fda_oncology_approval_notification
event date
2025-12-04
title
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma
drug or regimen
lisocabtagene maraleucel
approval date
2025-12-04
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved lisocabtagene maraleucel for adults with relapsed or refractory marginal zone lymphoma who have received at least two prior lines of systemic therapy.
indication source text
On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
opening context blocks
  1. On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
tumor type mapping hints
  1. lymphoma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-marginal-zone-lymphoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-marginal-zone-lymphoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-12-04
index description
On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy
provenance
retrieved at
2026-10-21T00:01:27.549785+00:00
local html
pages/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-marginal-zone-lymphoma.html
linked prescribing information
nct ids
  1. NCT04245839
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-12-03 · FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma
id
fda-a90b83cba53cf44c
event type
fda_oncology_approval_notification
event date
2025-12-03
title
FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma
drug or regimen
pirtobrutinib
approval date
2025-12-03
approval type
traditional
approval type evidence
traditional explicitly stated in title/opening
indication summary
FDA approved pirtobrutinib for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
indication source text
On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
opening context blocks
  1. On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
tumor type mapping hints
  1. lymphoma
  2. leukemia
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-12-03
index description
On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
provenance
retrieved at
2026-10-21T00:01:28.533417+00:00
local html
pages/fda-grants-traditional-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic.html
linked prescribing information
nct ids
quality flags
  1. multiple_regulatory_actions_require_indication_split
verification status
source_extracted_not_clinically_reviewed
2025-11-25 · FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma
id
fda-25cb7546eed078fb
event type
fda_oncology_approval_notification
event date
2025-11-25
title
FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma
drug or regimen
durvalumab
approval date
2025-11-25
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved durvalumab with fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma .
indication source text
On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
opening context blocks
  1. On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
tumor type mapping hints
  1. gastric
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-resectable-gastric-or-gastroesophageal-junction-adenocarcinoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-resectable-gastric-or-gastroesophageal-junction-adenocarcinoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-11-25
index description
On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
provenance
retrieved at
2026-10-21T00:01:29.582063+00:00
local html
pages/fda-approves-durvalumab-resectable-gastric-or-gastroesophageal-junction-adenocarcinoma.html
linked prescribing information
nct ids
  1. NCT04592913
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-11-21 · FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
id
fda-645462b4c10c2fb2
event type
fda_oncology_approval_notification
event date
2025-11-21
title
FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
drug or regimen
pembrolizumab with enfortumab vedotin-ejfv
approval date
2025-11-21
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph with enfortumab vedotin-ejfv as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer who are ineligible for cisplatin.
indication source text
On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.
opening context blocks
  1. On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.
tumor type mapping hints
  1. bladder
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-11-21
index description
On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.
provenance
retrieved at
2026-10-21T00:01:30.512844+00:00
local html
pages/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer.html
linked prescribing information
nct ids
  1. NCT03924895
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-11-19 · FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer
id
fda-a0a0b26c2d3a3702
event type
fda_oncology_approval_notification
event date
2025-11-19
title
FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer
drug or regimen
tarlatamab-dlle
approval date
2025-11-19
approval type
traditional
approval type evidence
traditional explicitly stated in title/opening
indication summary
FDA approved tarlatamab-dlle for adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
indication source text
On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
opening context blocks
  1. On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-11-19
index description
On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
provenance
retrieved at
2026-10-21T00:01:31.579677+00:00
local html
pages/fda-grants-traditional-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer.html
linked prescribing information
nct ids
  1. NCT05740566
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-11-19 · FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis
id
fda-4127658b41da6e41
event type
fda_oncology_approval_notification
event date
2025-11-19
title
FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis
drug or regimen
daratumumab and hyaluronidase-fihj
approval date
2025-11-19
approval type
traditional
approval type evidence
traditional explicitly stated in title/opening
indication summary
FDA approved daratumumab and hyaluronidase-fihj with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis. FDA granted accelerated approval for this indication in 2021.
indication source text
On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.
opening context blocks
  1. On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.
tumor type mapping hints
  1. al-amyloidosis
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-daratumumab-and-hyaluronidase-fihj-newly-diagnosed-light-chain
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-daratumumab-and-hyaluronidase-fihj-newly-diagnosed-light-chain
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-11-19
index description
On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.
provenance
retrieved at
2026-10-21T00:01:33.605483+00:00
local html
pages/fda-grants-traditional-approval-daratumumab-and-hyaluronidase-fihj-newly-diagnosed-light-chain.html
linked prescribing information
nct ids
  1. NCT03201965
quality flags
  1. multiple_regulatory_actions_require_indication_split
  2. may_be_supportive_care_or_nonmalignant_condition
verification status
source_extracted_not_clinically_reviewed
2025-11-19 · FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas
id
fda-2db0099d79952b23
event type
fda_oncology_approval_notification
event date
2025-11-19
title
FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas
drug or regimen
selumetinib
approval date
2025-11-19
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved selumetinib for adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas . FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
indication source text
On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
opening context blocks
  1. On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
tumor type mapping hints
  1. neurofibromatosis
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-adults-neurofibromatosis-type-1-symptomatic-inoperable-plexiform
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-adults-neurofibromatosis-type-1-symptomatic-inoperable-plexiform
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-11-19
index description
On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
provenance
retrieved at
2026-10-21T00:01:34.541418+00:00
local html
pages/fda-approves-selumetinib-adults-neurofibromatosis-type-1-symptomatic-inoperable-plexiform.html
linked prescribing information
nct ids
  1. NCT04924608
quality flags
  1. may_be_supportive_care_or_nonmalignant_condition
verification status
source_extracted_not_clinically_reviewed
2025-11-19 · FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
id
fda-26f47f4afac6d968
event type
fda_oncology_approval_notification
event date
2025-11-19
title
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
drug or regimen
sevabertinib
approval date
2025-11-19
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved sevabertinib, a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
indication source text
On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
opening context blocks
  1. On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
  2. FDA also approved the Oncomine Dx Target Test (Life Technologies Corporation) as a companion diagnostic device to aid in detectingHER2 (ERBB2) TKD activating mutations in patients with non-squamous NSCLC who may be eligible for treatment with sevabertinib.
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-non-squamous-non-small-cell-lung-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-non-squamous-non-small-cell-lung-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-11-19
index description
On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
provenance
retrieved at
2026-10-21T00:01:32.575654+00:00
local html
pages/fda-grants-accelerated-approval-sevabertinib-non-squamous-non-small-cell-lung-cancer.html
linked prescribing information
nct ids
  1. NCT05099172
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-11-18 · FDA approves epcoritamab-bysp for follicular lymphoma indications
id
fda-7a8e3c1432349ced
event type
fda_oncology_approval_notification
event date
2025-11-18
title
FDA approves epcoritamab-bysp for follicular lymphoma indications
drug or regimen
epcoritamab-bysp
approval date
2025-11-18
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma . The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy .
indication source text
On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024).
opening context blocks
  1. On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024).
tumor type mapping hints
  1. lymphoma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-epcoritamab-bysp-follicular-lymphoma-indications
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-epcoritamab-bysp-follicular-lymphoma-indications
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-11-18
index description
On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024).
provenance
retrieved at
2026-10-21T00:01:35.524732+00:00
local html
pages/fda-approves-epcoritamab-bysp-follicular-lymphoma-indications.html
linked prescribing information
nct ids
  1. NCT05409066
quality flags
  1. multiple_regulatory_actions_require_indication_split
verification status
source_extracted_not_clinically_reviewed
2025-11-13 · FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation
id
fda-970653d3c34dd8d5
event type
fda_oncology_approval_notification
event date
2025-11-13
title
FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation
drug or regimen
ziftomenib
approval date
2025-11-13
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved ziftomenib, a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options.
indication source text
On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.
opening context blocks
  1. On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.
tumor type mapping hints
  1. leukemia
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-11-13
index description
On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.
provenance
retrieved at
2026-10-21T00:01:37.638253+00:00
local html
pages/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation.html
linked prescribing information
nct ids
  1. NCT04067336
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-11-13 · FDA approves new interchangeable biosimilar to Perjeta
id
fda-5443f7e086270c53
event type
fda_oncology_approval_notification
event date
2025-11-13
title
FDA approves new interchangeable biosimilar to Perjeta
drug or regimen
pertuzumab-dpzb (Poherdy)
approval date
2025-11-13
approval type
interchangeable biosimilar
approval type evidence
interchangeable biosimilar explicitly stated in title/opening
indication summary
FDA approved Poherdy as an interchangeable biosimilar to Perjeta . This is the first approval of a biosimilar for Perjeta.
indication source text
On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta.
opening context blocks
  1. On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta.
  2. Poherdy is a HER2/neu receptor antagonist indicated for the following:
  3. use in combination with trastuzumab and docetaxel for adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
  4. use in combination with trastuzumab and chemotherapy asneoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.
  5. neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
  6. adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-interchangeable-biosimilar-perjeta
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-interchangeable-biosimilar-perjeta
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-11-13
index description
On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta.
provenance
retrieved at
2026-10-21T00:01:36.516059+00:00
local html
pages/fda-approves-new-interchangeable-biosimilar-perjeta.html
linked prescribing information
nct ids
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-11-06 · FDA approves daratumumab and hyaluronidase-fihj for high-risk smoldering multiple myeloma
id
fda-ebc8920f637fe1db
event type
fda_oncology_approval_notification
event date
2025-11-06
title
FDA approves daratumumab and hyaluronidase-fihj for high-risk smoldering multiple myeloma
drug or regimen
daratumumab and hyaluronidase-fihj
approval date
2025-11-06
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved daratumumab and hyaluronidase-fihj for adults with high-risk smoldering multiple myeloma .
indication source text
On November 6, 2025, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) for adults with high-risk smoldering multiple myeloma (SMM).
opening context blocks
  1. On November 6, 2025, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) for adults with high-risk smoldering multiple myeloma (SMM).
tumor type mapping hints
  1. myeloma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-high-risk-smoldering-multiple-myeloma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-high-risk-smoldering-multiple-myeloma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-11-06
index description
On November 6, 2025, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) for adults with high-risk smoldering multiple myeloma (SMM).
provenance
retrieved at
2026-10-21T00:01:38.525602+00:00
local html
pages/fda-approves-daratumumab-and-hyaluronidase-fihj-high-risk-smoldering-multiple-myeloma.html
linked prescribing information
nct ids
  1. NCT03301220
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-10-24 · FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation
id
fda-61ed478e73d4f4a0
event type
fda_oncology_approval_notification
event date
2025-10-24
title
FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation
drug or regimen
revumenib
approval date
2025-10-24
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved revumenib, a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
indication source text
On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
opening context blocks
  1. On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
tumor type mapping hints
  1. leukemia
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-10-24
index description
On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
provenance
retrieved at
2026-10-21T00:01:39.549417+00:00
local html
pages/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation.html
linked prescribing information
nct ids
  1. NCT04065399
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-10-23 · FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma
id
fda-29d861b96a3e37e4
event type
fda_oncology_approval_notification
event date
2025-10-23
title
FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma
drug or regimen
belantamab mafodotin-blmf
approval date
2025-10-23
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved belantamab mafodotin-blmf, a B-cell maturation antigen -directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
indication source text
On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
opening context blocks
  1. On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
tumor type mapping hints
  1. myeloma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belantamab-mafodotin-blmf-relapsed-or-refractory-multiple-myeloma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belantamab-mafodotin-blmf-relapsed-or-refractory-multiple-myeloma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-10-23
index description
On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
provenance
retrieved at
2026-10-21T00:01:40.531346+00:00
local html
pages/fda-approves-belantamab-mafodotin-blmf-relapsed-or-refractory-multiple-myeloma.html
linked prescribing information
nct ids
  1. NCT04246047
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-10-08 · FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma
id
fda-b93fc8a06f72822f
event type
fda_oncology_approval_notification
event date
2025-10-08
title
FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma
drug or regimen
cemiplimab-rwlc
approval date
2025-10-08
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved cemiplimab-rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
indication source text
On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.
opening context blocks
  1. On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.
tumor type mapping hints
  1. cutaneous-squamous-cell
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-adjuvant-treatment-cutaneous-squamous-cell-carcinoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-adjuvant-treatment-cutaneous-squamous-cell-carcinoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-10-08
index description
On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.
provenance
retrieved at
2026-10-21T00:01:41.600405+00:00
local html
pages/fda-approves-cemiplimab-rwlc-adjuvant-treatment-cutaneous-squamous-cell-carcinoma.html
linked prescribing information
nct ids
  1. NCT03969004
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-10-02 · FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer
id
fda-2552276b0d3a31f8
event type
fda_oncology_approval_notification
event date
2025-10-02
title
FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer
drug or regimen
lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs
approval date
2025-10-02
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.
indication source text
On October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.
opening context blocks
  1. On October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-combination-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-extensive
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-combination-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-extensive
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-10-02
index description
On October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.
provenance
retrieved at
2026-10-21T00:01:42.584783+00:00
local html
pages/fda-approves-lurbinectedin-combination-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-extensive.html
linked prescribing information
nct ids
  1. NCT05091567
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-09-25 · FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
id
fda-e6329c4a9f1a5704
event type
fda_oncology_approval_notification
event date
2025-09-25
title
FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
drug or regimen
imlunestrant
approval date
2025-09-25
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved imlunestrant, an estrogen receptor antagonist, for adults with estrogen receptor -positive, human epidermal growth factor 2 -negative, estrogen receptor-1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
indication source text
On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
opening context blocks
  1. On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
  2. FDA also approved the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with imlunestrant.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-09-25
index description
On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
provenance
retrieved at
2026-10-21T00:01:43.615852+00:00
local html
pages/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast.html
linked prescribing information
nct ids
  1. NCT04975308
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-09-19 · FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection
id
fda-7c04bb055e3ac31c
event type
fda_oncology_approval_notification
event date
2025-09-19
title
FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection
drug or regimen
pembrolizumab and berahyaluronidase alfa-pmph
approval date
2025-09-19
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection for adult and pediatric solid tumor indications approved for the intravenous formulation of pembrolizumab . See the prescribing information for the specific indications.
indication source text
On September 19, 2025, the Food and Drug Administration approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab (Keytruda, Merck). See the prescribing information for the specific indications.
opening context blocks
  1. On September 19, 2025, the Food and Drug Administration approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab (Keytruda, Merck). See the prescribing information for the specific indications.
tumor type mapping hints
  1. solid-tumors
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-09-19
index description
On September 19, 2025, the Food and Drug Administration approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab (Keytruda, Merck). See the prescribing information for the specific indications.
provenance
retrieved at
2026-10-21T00:01:44.580694+00:00
local html
pages/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection.html
linked prescribing information
nct ids
  1. NCT05722015
quality flags
  1. possible_multiple_indications_review
verification status
source_extracted_not_clinically_reviewed
2025-09-10 · FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas
id
fda-9327c9c5fe816ed3
event type
fda_oncology_approval_notification
event date
2025-09-10
title
FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas
drug or regimen
selumetinib
approval date
2025-09-10
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved selumetinib granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas . FDA previously approved selumetinib capsules for pediatric patients 2 years of age and older with NF1 who have symptomatic, inoperable PN.
indication source text
On September 10, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules for pediatric patients 2 years of age and older with NF1 who have symptomatic, inoperable PN.
opening context blocks
  1. On September 10, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules for pediatric patients 2 years of age and older with NF1 who have symptomatic, inoperable PN.
tumor type mapping hints
  1. neurofibromatosis
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-pediatric-patients-1-year-age-and-older-neurofibromatosis-type-1
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-pediatric-patients-1-year-age-and-older-neurofibromatosis-type-1
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-09-10
index description
On September 10, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules for pediatric patients 2 years of age and older with NF1 who have symptomatic, inoperable PN.
provenance
retrieved at
2026-10-21T00:01:45.550833+00:00
local html
pages/fda-approves-selumetinib-pediatric-patients-1-year-age-and-older-neurofibromatosis-type-1.html
linked prescribing information
nct ids
quality flags
  1. may_be_supportive_care_or_nonmalignant_condition
verification status
source_extracted_not_clinically_reviewed
2025-09-09 · FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer
id
fda-a71e076b93797c1c
event type
fda_oncology_approval_notification
event date
2025-09-09
title
FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer
drug or regimen
gemcitabine intravesical system
approval date
2025-09-09
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved gemcitabine intravesical system for adults with Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. Gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.
indication source text
On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.
opening context blocks
  1. On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.
tumor type mapping hints
  1. bladder
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gemcitabine-intravesical-system-non-muscle-invasive-bladder-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gemcitabine-intravesical-system-non-muscle-invasive-bladder-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-09-09
index description
On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.
provenance
retrieved at
2026-10-21T00:01:46.580769+00:00
local html
pages/fda-approves-gemcitabine-intravesical-system-non-muscle-invasive-bladder-cancer.html
linked prescribing information
nct ids
  1. NCT04640623
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-08-08 · FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations
id
fda-7d091a8440ce03e5
event type
fda_oncology_approval_notification
event date
2025-08-08
title
FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations
drug or regimen
zongertinib
approval date
2025-08-08
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved zongertinib, a kinase inhibitor, for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.
indication source text
On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.
opening context blocks
  1. On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.
  2. FDA also approved the Oncomine Dx Target Test (Life Technologies Corporation) as a companion diagnostic device to aid in detecting HER2 (ERBB2) TKD activating mutations in patients with non-squamous NSCLC who may be eligible for treatment with zongertinib.
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-08-08
index description
On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.
provenance
retrieved at
2026-10-21T00:01:47.571236+00:00
local html
pages/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations.html
linked prescribing information
nct ids
  1. NCT04886804
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-08-06 · FDA grants accelerated approval to dordaviprone for diffuse midline glioma
id
fda-a3a29918b1e0c594
event type
fda_oncology_approval_notification
event date
2025-08-06
title
FDA grants accelerated approval to dordaviprone for diffuse midline glioma
drug or regimen
dordaviprone
approval date
2025-08-06
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved dordaviprone, a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
indication source text
On August 6, 2025, the Food and Drug Administration granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals, Inc.), a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
opening context blocks
  1. On August 6, 2025, the Food and Drug Administration granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals, Inc.), a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
  2. This represents the first FDA approval of a systemic therapy for H3 K27M-mutant diffuse midline glioma.
tumor type mapping hints
  1. glioma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-08-06
index description
On August 6, 2025, the Food and Drug Administration granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals, Inc.), a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
provenance
retrieved at
2026-10-21T00:01:48.634918+00:00
local html
pages/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma.html
linked prescribing information
nct ids
  1. NCT02525692
  2. NCT03134131
  3. NCT03295396
  4. NCT03416530
  5. NCT05392374
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-07-02 · FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
id
fda-29a56844a8ee9ae3
event type
fda_oncology_approval_notification
event date
2025-07-02
title
FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
drug or regimen
sunvozertinib
approval date
2025-07-02
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved sunvozertinib for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
indication source text
On July 2, 2025, the Food and Drug Administration granted accelerated approval to sunvozertinib (Zegfrovy, Dizal (Jiangsu) Pharmaceutical Co., Ltd.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
opening context blocks
  1. On July 2, 2025, the Food and Drug Administration granted accelerated approval to sunvozertinib (Zegfrovy, Dizal (Jiangsu) Pharmaceutical Co., Ltd.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
  2. Today, FDA also approved the Oncomine Dx Express Test (Life Technologies Corporation) as a companion diagnostic device to aid in detecting EGFR exon 20 insertion mutations in patients with NSCLC who may be eligible for treatment with Zegfrovy.
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-07-02
index description
On July 2, 2025, the Food and Drug Administration granted accelerated approval to sunvozertinib (Zegfrovy, Dizal (Jiangsu) Pharmaceutical Co., Ltd.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
provenance
retrieved at
2026-10-21T00:01:49.663231+00:00
local html
pages/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20.html
linked prescribing information
nct ids
  1. NCT03974022
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-07-02 · FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma
id
fda-20922be08c90e6ba
event type
fda_oncology_approval_notification
event date
2025-07-02
title
FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma
drug or regimen
linvoseltamab-gcpt
approval date
2025-07-02
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved linvoseltamab-gcpt, a bispecific B-cell maturation antigen -directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
indication source text
On July 2, 2025, the Food and Drug Administration granted accelerated approval to linvoseltamab-gcpt (Lynozyfic, Regeneron Pharmaceuticals, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.
opening context blocks
  1. On July 2, 2025, the Food and Drug Administration granted accelerated approval to linvoseltamab-gcpt (Lynozyfic, Regeneron Pharmaceuticals, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.
tumor type mapping hints
  1. myeloma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-07-02
index description
On July 2, 2025, the Food and Drug Administration granted accelerated approval to linvoseltamab-gcpt (Lynozyfic, Regeneron Pharmaceuticals, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.
provenance
retrieved at
2026-10-21T00:01:50.634456+00:00
local html
pages/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma.html
linked prescribing information
nct ids
  1. NCT03761108
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-06-23 · FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer
id
fda-29743855ffd67cd9
event type
fda_oncology_approval_notification
event date
2025-06-23
title
FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer
drug or regimen
datopotamab deruxtecan-dlnk
approval date
2025-06-23
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved datopotamab deruxtecan-dlnk for adults with locally advanced or metastatic epidermal growth factor receptor -mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy.
indication source text
On June 23, 2025, the Food and Drug Administration granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.
opening context blocks
  1. On June 23, 2025, the Food and Drug Administration granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-06-23
index description
On June 23, 2025, the Food and Drug Administration granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.
provenance
retrieved at
2026-10-21T00:01:51.580680+00:00
local html
pages/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer.html
linked prescribing information
nct ids
  1. NCT04484142
  2. NCT04656652
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-06-18 · FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
id
fda-fb6075995c0aa4db
event type
fda_oncology_approval_notification
event date
2025-06-18
title
FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
drug or regimen
tafasitamab-cxix
approval date
2025-06-18
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved tafasitamab-cxix with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma .
indication source text
On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL).
opening context blocks
  1. On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL).
tumor type mapping hints
  1. lymphoma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tafasitamab-cxix-relapsed-or-refractory-follicular-lymphoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tafasitamab-cxix-relapsed-or-refractory-follicular-lymphoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-06-18
index description
On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL).
provenance
retrieved at
2026-10-21T00:01:52.633527+00:00
local html
pages/fda-approves-tafasitamab-cxix-relapsed-or-refractory-follicular-lymphoma.html
linked prescribing information
nct ids
  1. NCT04680052
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-06-12 · FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma
id
fda-9dafa5ab92723dbc
event type
fda_oncology_approval_notification
event date
2025-06-12
title
FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma
drug or regimen
neoadjuvant and adjuvant pembrolizumab
approval date
2025-06-12
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved pembrolizumab for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin after surgery, and then as a single agent.
indication source text
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin after surgery, and then as a single agent.
opening context blocks
  1. On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin after surgery, and then as a single agent.
  2. This is the first approval for HNSCC in 6 years and the first overall perioperative approval for locally advanced HNSCC.
tumor type mapping hints
  1. head-and-neck
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-and-adjuvant-pembrolizumab-resectable-locally-advanced-head-and-neck
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-and-adjuvant-pembrolizumab-resectable-locally-advanced-head-and-neck
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-06-12
index description
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin after surgery, and then as a single agent.
provenance
retrieved at
2026-10-21T00:01:53.598969+00:00
local html
pages/fda-approves-neoadjuvant-and-adjuvant-pembrolizumab-resectable-locally-advanced-head-and-neck.html
linked prescribing information
nct ids
  1. NCT03765918
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-06-12 · FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
id
fda-4ef07a829e92c511
event type
fda_oncology_approval_notification
event date
2025-06-12
title
FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
drug or regimen
mitomycin intravesical solution
approval date
2025-06-12
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved mitomycin intravesical solution for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer .
indication source text
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
opening context blocks
  1. On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
tumor type mapping hints
  1. bladder
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mitomycin-intravesical-solution-recurrent-low-grade-intermediate-risk-non-muscle
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mitomycin-intravesical-solution-recurrent-low-grade-intermediate-risk-non-muscle
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-06-12
index description
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
provenance
retrieved at
2026-10-21T00:01:54.686118+00:00
local html
pages/fda-approves-mitomycin-intravesical-solution-recurrent-low-grade-intermediate-risk-non-muscle.html
linked prescribing information
nct ids
  1. NCT05243550
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-06-11 · FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
id
fda-0f7fd15d941ce1a4
event type
fda_oncology_approval_notification
event date
2025-06-11
title
FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
drug or regimen
taletrectinib
approval date
2025-06-11
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved taletrectinib, a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer .
indication source text
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
opening context blocks
  1. On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-06-11
index description
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
provenance
retrieved at
2026-10-21T00:01:55.593249+00:00
local html
pages/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer.html
linked prescribing information
nct ids
  1. NCT04395677
  2. NCT04919811
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-06-03 · FDA approves darolutamide for metastatic castration-sensitive prostate cancer
id
fda-6a8e7d45487d2138
event type
fda_oncology_approval_notification
event date
2025-06-03
title
FDA approves darolutamide for metastatic castration-sensitive prostate cancer
drug or regimen
darolutamide
approval date
2025-06-03
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved darolutamide for metastatic castration-sensitive prostate cancer . The FDA previously approved darolutamide in combination with docetaxel for mCSPC.
indication source text
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA previously approved darolutamide in combination with docetaxel for mCSPC.
opening context blocks
  1. On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA previously approved darolutamide in combination with docetaxel for mCSPC.
tumor type mapping hints
  1. prostate
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-metastatic-castration-sensitive-prostate-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-metastatic-castration-sensitive-prostate-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-06-03
index description
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA previously approved darolutamide in combination with docetaxel for mCSPC.
provenance
retrieved at
2026-10-21T00:01:56.634163+00:00
local html
pages/fda-approves-darolutamide-metastatic-castration-sensitive-prostate-cancer.html
linked prescribing information
nct ids
  1. NCT02799602
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-05-15 · FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
id
fda-8dc0436208642c00
event type
fda_oncology_approval_notification
event date
2025-05-15
title
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
drug or regimen
retifanlimab-dlwr with carboplatin/paclitaxel and as monotherapy
approval date
2025-05-15
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved retifanlimab-dlwr with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal . The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
indication source text
On May 15, 2025, the Food and Drug Administration approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
opening context blocks
  1. On May 15, 2025, the Food and Drug Administration approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
tumor type mapping hints
  1. anal
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-retifanlimab-dlwr-carboplatin-and-paclitaxel-and-single-agent-squamous-cell-carcinoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-retifanlimab-dlwr-carboplatin-and-paclitaxel-and-single-agent-squamous-cell-carcinoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-05-15
index description
On May 15, 2025, the Food and Drug Administration approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
provenance
retrieved at
2026-10-21T00:01:57.630797+00:00
local html
pages/fda-approves-retifanlimab-dlwr-carboplatin-and-paclitaxel-and-single-agent-squamous-cell-carcinoma.html
linked prescribing information
nct ids
  1. NCT03597295
  2. NCT04472429
quality flags
  1. multiple_regulatory_actions_require_indication_split
verification status
source_extracted_not_clinically_reviewed
2025-05-14 · FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression
id
fda-2f7de233a4d4da06
event type
fda_oncology_approval_notification
event date
2025-05-14
title
FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression
drug or regimen
telisotuzumab vedotin-tllv
approval date
2025-05-14
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved telisotuzumab vedotin-tllv, a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression [≥50% of tumor cells with strong staining], as determined by an FDA-approved test, who have received a prior systemic therapy.
indication source text
On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.
opening context blocks
  1. On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.
  2. FDA also approved the VENTANA MET (SP44) RxDx Assay (Roche Diagnostics) as a companion diagnostic test to aid in detecting c-Met protein overexpression in patients with non-squamous NSCLC who may be eligible for treatment with Emrelis.
tumor type mapping hints
  1. lung
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-05-14
index description
On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.
provenance
retrieved at
2026-10-21T00:01:58.641122+00:00
local html
pages/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression.html
linked prescribing information
nct ids
  1. NCT03539536
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-05-14 · FDA approves belzutifan for pheochromocytoma or paraganglioma
id
fda-1b5d5b6918dc4f02
event type
fda_oncology_approval_notification
event date
2025-05-14
title
FDA approves belzutifan for pheochromocytoma or paraganglioma
drug or regimen
belzutifan
approval date
2025-05-14
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved belzutifan for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma . This represents the first FDA approval of an oral therapy for PPGL.
indication source text
On May 14, 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL.
opening context blocks
  1. On May 14, 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL.
tumor type mapping hints
  1. pheochromocytoma-paraganglioma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-05-14
index description
On May 14, 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL.
provenance
retrieved at
2026-10-21T00:01:59.612841+00:00
local html
pages/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma.html
linked prescribing information
nct ids
  1. NCT04924075
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-05-08 · FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer
id
fda-bb4491d3eb484f1e
event type
fda_oncology_approval_notification
event date
2025-05-08
title
FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer
drug or regimen
the combination of avutometinib and defactinib
approval date
2025-05-08
approval type
accelerated
approval type evidence
accelerated explicitly stated in title/opening
indication summary
FDA approved the combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.
indication source text
On May 8, 2025, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
opening context blocks
  1. On May 8, 2025, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
tumor type mapping hints
  1. ovarian
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-05-08
index description
On May 8, 2025, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
provenance
retrieved at
2026-10-21T00:02:00.635888+00:00
local html
pages/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low.html
linked prescribing information
nct ids
  1. NCT04625270
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-04-23 · FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma
id
fda-e43d505c8aaeb35e
event type
fda_oncology_approval_notification
event date
2025-04-23
title
FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma
drug or regimen
penpulimab-kcqx
approval date
2025-04-23
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma . FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
indication source text
On April 23, 2025, the Food and Drug Administration approved penpulimab-kcqx (Akeso Biopharma Co., Ltd.) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
opening context blocks
  1. On April 23, 2025, the Food and Drug Administration approved penpulimab-kcqx (Akeso Biopharma Co., Ltd.) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
tumor type mapping hints
  1. head-and-neck
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-penpulimab-kcqx-non-keratinizing-nasopharyngeal-carcinoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-penpulimab-kcqx-non-keratinizing-nasopharyngeal-carcinoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-04-23
index description
On April 23, 2025, the Food and Drug Administration approved penpulimab-kcqx (Akeso Biopharma Co., Ltd.) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC).
provenance
retrieved at
2026-10-21T00:02:01.666628+00:00
local html
pages/fda-approves-penpulimab-kcqx-non-keratinizing-nasopharyngeal-carcinoma.html
linked prescribing information
nct ids
  1. NCT03866967
  2. NCT04974398
quality flags
  1. multiple_regulatory_actions_require_indication_split
verification status
source_extracted_not_clinically_reviewed
2025-04-11 · FDA approves nivolumab with ipilimumab for unresectable or metastatic hepatocellular carcinoma
id
fda-5a12fc6862fd1c47
event type
fda_oncology_approval_notification
event date
2025-04-11
title
FDA approves nivolumab with ipilimumab for unresectable or metastatic hepatocellular carcinoma
drug or regimen
nivolumab with ipilimumab
approval date
2025-04-11
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved nivolumab with ipilimumab for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma .
indication source text
On April 11, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
opening context blocks
  1. On April 11, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
tumor type mapping hints
  1. liver
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-hepatocellular-carcinoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-hepatocellular-carcinoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-04-11
index description
On April 11, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
provenance
retrieved at
2026-10-21T00:02:02.710361+00:00
local html
pages/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-hepatocellular-carcinoma.html
linked prescribing information
nct ids
  1. NCT04039607
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-04-08 · FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
id
fda-b3dfa41ec820a8c2
event type
fda_oncology_approval_notification
event date
2025-04-08
title
FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
drug or regimen
nivolumab with ipilimumab
approval date
2025-04-08
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved nivolumab with ipilimumab for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer . The FDA also converted the accelerated approval to regular approval for single agent nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic CRC, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.
indication source text
On April 8, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated approval to regular approval for single agent nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic CRC, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.
opening context blocks
  1. On April 8, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated approval to regular approval for single agent nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic CRC, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.
tumor type mapping hints
  1. colorectal
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-04-08
index description
On April 8, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated approval to regular approval for single agent nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic CRC, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.
provenance
retrieved at
2026-10-21T00:02:03.708578+00:00
local html
pages/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer.html
linked prescribing information
nct ids
  1. NCT04008030
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-03-28 · FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
id
fda-f48b23d099252406
event type
fda_oncology_approval_notification
event date
2025-03-28
title
FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
drug or regimen
lutetium Lu 177 vipivotide tetraxetan
approval date
2025-03-28
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved lutetium Lu 177 vipivotide tetraxetan to include adults with prostate-specific membrane antigen -positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibitor therapy and are considered appropriate to delay taxane-based chemotherapy.
indication source text
On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.
opening context blocks
  1. On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.
  2. Patients with previously treated mCRPC should be selected for Pluvicto using Locametz (active ingredient gallium Ga 68 gozetotide) or another approved PSMA positron emission tomography (PET) product based on PSMA expression in tumors.
tumor type mapping hints
  1. prostate
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-03-28
index description
On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.
provenance
retrieved at
2026-10-21T00:02:05.651792+00:00
local html
pages/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication.html
linked prescribing information
nct ids
  1. NCT04689828
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-03-28 · FDA approves durvalumab for muscle invasive bladder cancer
id
fda-cdab6bdb583859b8
event type
fda_oncology_approval_notification
event date
2025-03-28
title
FDA approves durvalumab for muscle invasive bladder cancer
drug or regimen
durvalumab
approval date
2025-03-28
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved durvalumab with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer .
indication source text
On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer (MIBC).
opening context blocks
  1. On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer (MIBC).
tumor type mapping hints
  1. bladder
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-muscle-invasive-bladder-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-muscle-invasive-bladder-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-03-28
index description
On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer (MIBC).
provenance
retrieved at
2026-10-21T00:02:04.665516+00:00
local html
pages/fda-approves-durvalumab-muscle-invasive-bladder-cancer.html
linked prescribing information
nct ids
  1. NCT03732677
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-03-26 · FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET
id
fda-9cc973464c58ebe6
event type
fda_oncology_approval_notification
event date
2025-03-26
title
FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET
drug or regimen
cabozantinib
approval date
2025-03-26
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved cabozantinib for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors .
indication source text
On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
opening context blocks
  1. On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
tumor type mapping hints
  1. pancreatic
  2. neuroendocrine
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-03-26
index description
On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
provenance
retrieved at
2026-10-21T00:02:06.728510+00:00
local html
pages/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet.html
linked prescribing information
nct ids
  1. NCT03375320
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-03-19 · FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)
id
fda-695234945b5fc3e9
event type
fda_oncology_approval_notification
event date
2025-03-19
title
FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)
drug or regimen
pembrolizumab
approval date
2025-03-19
approval type
traditional
approval type evidence
traditional explicitly stated in title/opening
indication summary
FDA approved pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 .
indication source text
On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
opening context blocks
  1. On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
  2. Pembrolizumab previously received accelerated approval for this indication on May 5, 2021, based on interim analysis of the trial described below.
tumor type mapping hints
  1. gastric
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-03-19
index description
On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
provenance
retrieved at
2026-10-21T00:02:07.662630+00:00
local html
pages/fda-approves-pembrolizumab-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma.html
linked prescribing information
nct ids
  1. NCT03615326
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-02-14 · FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor
id
fda-969b151e3e3b8fb3
event type
fda_oncology_approval_notification
event date
2025-02-14
title
FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor
drug or regimen
vimseltinib
approval date
2025-02-14
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved vimseltinib, a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
indication source text
On February 14, 2025, the Food and Drug Administration approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
opening context blocks
  1. On February 14, 2025, the Food and Drug Administration approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
tumor type mapping hints
  1. tenosynovial-giant-cell-tumor
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-02-14
index description
On February 14, 2025, the Food and Drug Administration approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
provenance
retrieved at
2026-10-21T00:02:08.662293+00:00
local html
pages/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor.html
linked prescribing information
nct ids
  1. NCT05059262
quality flags
  1. may_be_supportive_care_or_nonmalignant_condition
verification status
source_extracted_not_clinically_reviewed
2025-02-11 · FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma
id
fda-7cfc622364fa169f
event type
fda_oncology_approval_notification
event date
2025-02-11
title
FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma
drug or regimen
brentuximab vedotin with lenalidomide and rituximab
approval date
2025-02-11
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved brentuximab vedotin in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma, after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation or CAR T-cell therapy.
indication source text
On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.
opening context blocks
  1. On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.
tumor type mapping hints
  1. lymphoma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brentuximab-vedotin-lenalidomide-and-rituximab-relapsed-or-refractory-large-b-cell
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brentuximab-vedotin-lenalidomide-and-rituximab-relapsed-or-refractory-large-b-cell
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-02-12
index description
On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.
provenance
retrieved at
2026-10-21T00:02:09.677236+00:00
local html
pages/fda-approves-brentuximab-vedotin-lenalidomide-and-rituximab-relapsed-or-refractory-large-b-cell.html
linked prescribing information
nct ids
  1. NCT04404283
quality flags
  1. index_date_differs_from_approval_date
verification status
source_extracted_not_clinically_reviewed
2025-02-11 · FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
id
fda-1737eb0935b01c53
event type
fda_oncology_approval_notification
event date
2025-02-11
title
FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
drug or regimen
mirdametinib
approval date
2025-02-11
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved mirdametinib, a kinase inhibitor, for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection.
indication source text
On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
opening context blocks
  1. On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
tumor type mapping hints
  1. neurofibromatosis
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-02-11
index description
On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
provenance
retrieved at
2026-10-21T00:02:10.696904+00:00
local html
pages/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic.html
linked prescribing information
nct ids
  1. NCT03962543
quality flags
  1. may_be_supportive_care_or_nonmalignant_condition
verification status
source_extracted_not_clinically_reviewed
2025-01-27 · FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
id
fda-6c8690a10014b840
event type
fda_oncology_approval_notification
event date
2025-01-27
title
FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
drug or regimen
fam-trastuzumab deruxtecan-nxki
approval date
2025-01-27
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved fam-trastuzumab deruxtecan-nxki for unresectable or metastatic hormone receptor -positive, HER2-low or HER2-ultralow breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
indication source text
On January 27, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
opening context blocks
  1. On January 27, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
  2. FDA also approved the Ventana’s PATHWAY anti-HER-2 (4B5) Rabbit Monoclonal Primary Antibody assay as a companion diagnostic device to identify patients with HER2-ultralow (IHC 0 with membrane staining) breast cancer for treatment with Enhertu. This assay was previously approved to identify patients with HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer for treatment with Enhertu.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-01-27
index description
On January 27, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
provenance
retrieved at
2026-10-21T00:02:12.678956+00:00
local html
pages/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2.html
linked prescribing information
nct ids
  1. NCT04494425
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-01-21 · FDA approves treosulfan with fludarabine as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS
id
fda-eed3ef224dcd705a
event type
fda_oncology_approval_notification
event date
2025-01-21
title
FDA approves treosulfan with fludarabine as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS
drug or regimen
treosulfan with fludarabine
approval date
2025-01-21
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved treosulfan, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia or myelodysplastic syndrome .
indication source text
On January 21, 2025, the Food and Drug Administration approved treosulfan (Grafapex, medac GmbH), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
opening context blocks
  1. On January 21, 2025, the Food and Drug Administration approved treosulfan (Grafapex, medac GmbH), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
tumor type mapping hints
  1. leukemia
  2. myelodysplastic
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-treosulfan-fludarabine-preparative-regimen-allohsct-adult-and-pediatric-patients-aml-or
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-treosulfan-fludarabine-preparative-regimen-allohsct-adult-and-pediatric-patients-aml-or
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-02-06
index description
On January 21, 2025, the Food and Drug Administration approved treosulfan (Grafapex, medac GmbH), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
provenance
retrieved at
2026-10-21T00:02:11.703653+00:00
local html
pages/fda-approves-treosulfan-fludarabine-preparative-regimen-allohsct-adult-and-pediatric-patients-aml-or.html
linked prescribing information
nct ids
  1. NCT00822393
quality flags
  1. index_date_differs_from_approval_date
verification status
source_extracted_not_clinically_reviewed
2025-01-17 · FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
id
fda-718ebee3ee60ca74
event type
fda_oncology_approval_notification
event date
2025-01-17
title
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
drug or regimen
datopotamab deruxtecan-dlnk
approval date
2025-01-17
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved datopotamab deruxtecan-dlnk, a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic, hormone receptor -positive, human epidermal growth factor receptor 2 -negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
indication source text
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC1+ or IHC2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
opening context blocks
  1. On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC1+ or IHC2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
tumor type mapping hints
  1. breast
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-01-17
index description
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC1+ or IHC2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
provenance
retrieved at
2026-10-21T00:02:14.692404+00:00
local html
pages/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast.html
linked prescribing information
nct ids
  1. NCT05104866
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-01-16 · FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma
id
fda-7fa68eece0cf7e41
event type
fda_oncology_approval_notification
event date
2025-01-16
title
FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma
drug or regimen
acalabrutinib with bendamustine and rituximab
approval date
2025-01-16
approval type
traditional
approval type evidence
traditional explicitly stated in title/opening
indication summary
FDA approved acalabrutinib with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation .
indication source text
On January 16, 2025, the Food and Drug Administration granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
opening context blocks
  1. On January 16, 2025, the Food and Drug Administration granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
  2. FDA also granted traditional approval to acalabrutinib as a single agent for adults with previously treated MCL. Acalabrutinib received accelerated approval for this indication in 2017.
tumor type mapping hints
  1. lymphoma
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-acalabrutinib-bendamustine-and-rituximab-previously-untreated-mantle-cell-lymphoma
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-acalabrutinib-bendamustine-and-rituximab-previously-untreated-mantle-cell-lymphoma
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-01-16
index description
On January 16, 2025, the Food and Drug Administration granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
provenance
retrieved at
2026-10-21T00:02:16.708472+00:00
local html
pages/fda-approves-acalabrutinib-bendamustine-and-rituximab-previously-untreated-mantle-cell-lymphoma.html
linked prescribing information
nct ids
  1. NCT02972840
quality flags
verification status
source_extracted_not_clinically_reviewed
2025-01-16 · FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer
id
fda-616257e683ecd313
event type
fda_oncology_approval_notification
event date
2025-01-16
title
FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer
drug or regimen
sotorasib with panitumumab
approval date
2025-01-16
approval type
Source null
approval type evidence
FDA says approved; pathway not explicitly stated in title/opening, so not inferred
indication summary
FDA approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
indication source text
On January 16, 2025, the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
opening context blocks
  1. On January 16, 2025, the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
  2. Today, the FDA also approved the therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) as a companion diagnostic device to aid in identifying patients with colorectal cancer whose tumors harbor KRAS G12C mutations and who may be eligible for Lumakras with Vectibix.
tumor type mapping hints
  1. colorectal
mapping status
heuristic_requires_editorial_review
regulatory meaning
Dated US FDA approval notification for the stated use; not a guideline recommendation, treatment ranking, proof of survival benefit, or confirmation the indication remains current. Reconcile current label, subsequent changes and withdrawal status.
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sotorasib-panitumumab-kras-g12c-mutated-colorectal-cancer
evidence source url
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sotorasib-panitumumab-kras-g12c-mutated-colorectal-cancer
source basis
individual FDA notification page
source locator
Page title and opening approval paragraph; exact text and additional introductory blocks preserved
index date
2025-01-16
index description
On January 16, 2025, the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
provenance
retrieved at
2026-10-21T00:02:15.725672+00:00
local html
pages/fda-approves-sotorasib-panitumumab-kras-g12c-mutated-colorectal-cancer.html
linked prescribing information
nct ids
  1. NCT05198934
quality flags
verification status
source_extracted_not_clinically_reviewed